Kovarík J, Svec F, Zemanová D
Neoplasma. 1977;24(5):475-86.
The antileukemic activity of cis-diamminedichloroplatinum (PDD) was studied in rats bearing myelogenous leukemia RBA-Le. Clinical picture, changes in life-span, hematological indices and weight changes were used to assess the effectiveness of the therapy. Maximum effectiveness was noted when PDD was given in combination with Methotrexate (MTX) and Poly I:C, respectively. The mean life-span of the rats treated with PDD and MTX was prolonged to 37 days that is an increase of 147 percent of the control level. Furthermore 20 percent of the treated animals survived symptom-free for more than 60 days. Out of 20 animals receiving PDD in combination with Poly I:C 6 rats survived 60 days symptom-free. In remaining 14 animals who finally died on leukemia an 85 percent increase in life-span was noted. Only slight increase in life-span was recorded in those groups treated with PDD alone and in combination with Cyclophosphamide regardless of dosage schedule. The general toxicity of PDD therapy is discussed.
在患有骨髓性白血病RBA-Le的大鼠中研究了顺二氯二氨铂（PDD）的抗白血病活性。通过临床症状、生存期变化、血液学指标和体重变化来评估治疗效果。当PDD分别与甲氨蝶呤（MTX）和聚肌胞苷酸（Poly I:C）联合使用时，观察到最大疗效。接受PDD和MTX治疗的大鼠平均生存期延长至37天，比对照水平增加了147%。此外，20%的治疗动物无症状存活超过60天。在20只接受PDD与Poly I:C联合治疗的动物中，6只大鼠无症状存活60天。在最终死于白血病的其余14只动物中，观察到生存期增加了85%。无论给药方案如何，单独使用PDD以及与环磷酰胺联合使用的组中，仅记录到生存期略有增加。讨论了PDD治疗的一般毒性。
